Key result
Selective use of intravenous antiplatelet agents, including glycoprotein IIb/IIIa inhibitors and cangrelor, reduces the risk of periprocedural thrombosis during percutaneous coronary intervention.
Why the study?
Do intravenous antiplatelet agents reduce the risk of periprocedural thrombosis in patients undergoing PCI?
Do intravenous antiplatelet agents reduce the risk of periprocedural thrombosis in patients undergoing PCI?
Intravenous antiplatelet agents such as cangrelor and glycoprotein IIb/IIIa inhibitors overcome the unpredictable onset of oral agents, effectively reducing periprocedural thrombosis risk during PCI.
Answers are grounded in this paper and cite their sources.
May support selective IV antiplatelet use in high-risk PCI; leaves open need for prospective trials.
Oral ADP-receptor antagonists combined with aspirin are the standard for dual antiplatelet therapy (DAPT) during percutaneous coronary intervention (PCI). However, the oral route of administration of ADP-receptor antagonists leaves them vulnerable to unpredictable and often inadequate platelet inhibition at the time of PCI, while their prolonged effects often lead to the decision not to load them prior to PCI. Intravenous antiplatelet agents, including glycoprotein IIb/IIIa inhibitors (GPI) and cangrelor, a reversible P2Y12 inhibitor, address these shortcomings. In June 2015, the US FDA approved cangrelor for the prevention of thrombotic events associated with coronary stenting. This review examines the current state of peri-PCI DAPT and demonstrates that the selective use of GPIs and intravenous ADP-antagonist agents reduces the risk of periprocedural thrombosis.
No takes yet. Share an insight, caveat, or question.
Tyler et al. (2016) conducted a review in Percutaneous coronary intervention (PCI). Intravenous antiplatelet agents (glycoprotein IIb/IIIa inhibitors and cangrelor) vs. Oral ADP-receptor antagonists was evaluated on Periprocedural thrombosis. Selective use of intravenous antiplatelet agents, including glycoprotein IIb/IIIa inhibitors and cangrelor, reduces the risk of periprocedural thrombosis during percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: